Comparison
Omega-3 (EPA/DHA) vs Semax
Side-by-side of Omega-3 (EPA/DHA) and Semax. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Omega-3 (EPA/DHA)
Omega 3 fish oil profile: EPA/DHA marine fatty acids, 2-4 g/day cuts triglycerides 20-30%, REDUCE-IT showed 25% cardiovascular risk reduction on icosapent eth.
Semax
Semax peptide benefits: nootropic ACTH(4-10) analog without corticotropic activity. Cognitive enhancement, neuroprotection, intranasal dosing, Russian stroke.
Effects at a glance
Omega-3 (EPA/DHA)
- •Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
- •REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
- •Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
- •Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
- •Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
- •Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state
Semax
- •Synthetic heptapeptide analog of ACTH(4-10) developed in Russia in the 1980s
- •Approved in Russia for ischemic stroke, cognitive impairment, and cerebrovascular disorders
- •Lacks the corticotropic activity of native ACTH due to the Pro-Gly-Pro stabilizing tail
- •Russian RCTs report improved cognitive recovery in acute ischemic stroke versus standard care
- •Modulates BDNF and NGF expression and dopaminergic signaling in preclinical models
- •Standard route is intranasal; not FDA approved; research-use-only outside Russia
Side-by-side
| Attribute | Omega-3 (EPA/DHA) | Semax |
|---|---|---|
| Category | supplement | peptide |
| Also known as | fish oil, EPA, DHA, marine omega-3 | Met-Glu-His-Phe-Pro-Gly-Pro, ACTH(4-10) Pro-Gly-Pro analog |
| Half-life (hr) ↗ | 48 | 0.5 |
| Typical dose (mg) ↗ | 2000 | 0.6 |
| Dosing frequency | 1 to 2 times daily with food | 2-3x daily (intranasal) |
| Routes | oral | intranasal |
| Onset (hr) | 4 | 0.5 |
| Peak (hr) | 12 | 2 |
| Molecular weight | 302.45 | 813.94 |
| Molecular formula | C20H30O2 (EPA); C22H32O2 (DHA) | C37H51N9O10S |
| Mechanism | Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function. | Modulates BDNF and NGF expression in hippocampus and cortex, enhances dopaminergic and serotonergic signaling, and reduces oxidative stress markers in preclinical ischemia models. Lacks corticotropic activity of native ACTH. |
| Legal status | Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia | Approved in Russia for stroke and cognitive disorders; not FDA approved; research-use-only grey market elsewhere |
| WADA status | allowed | unknown |
| DEA / Rx | Not scheduled | Not FDA approved; not scheduled; research-chemical status outside Russia |
| Pregnancy | Recommended at 200 to 600 mg DHA/day for fetal development | Not recommended; insufficient data |
| CAS | 10417-94-4 | 80714-61-0 |
| PubChem CID | 446284 | 9811102 |
| Wikidata | Q207688 | Q4413083 |
Safety profile
Omega-3 (EPA/DHA)
Common side effects
- fishy aftertaste
- eructation (fish burps)
- mild dyspepsia
- loose stools at high doses
Contraindications
- fish allergy (use algal omega-3 alternative)
- active bleeding disorders
- scheduled surgery (discontinue 5-7 days prior)
Interactions
- warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
- aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
- statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
- antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)
Semax
Common side effects
- mild nasal irritation
- transient mild headache
- rare mild euphoria or activation
Contraindications
- pregnancy
- lactation
- acute psychotic disorder
- severe hypertension (caution due to mild activating effect)
Interactions
- stimulants (caffeine, amphetamines): potential additive activation; monitor for overstimulation(minor)
- antipsychotics: theoretical antagonism via dopaminergic modulation(minor)
Which Should You Take?
Omega-3 (EPA/DHA) comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Semax is the right call when one of the conditionals below applies.
- → If your priority is cardiovascular health, pick Omega-3 (EPA/DHA).
- → If your priority is healthspan extension, pick Omega-3 (EPA/DHA).
- → If your priority is long-term neuroprotection, pick Semax.
- → If your priority is stroke recovery, pick Semax.
Edge case: If you want to avoid research-only / gray-market sourcing, Omega-3 (EPA/DHA) is the more accessible choice.
Default choice: Omega-3 (EPA/DHA). Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Semax only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Omega-3 (EPA/DHA) and Semax?
Omega-3 (EPA/DHA) and Semax differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Omega-3 (EPA/DHA) or Semax?
Omega-3 (EPA/DHA) half-life is 48 hours; Semax half-life is 0.5 hours.
Can you stack Omega-3 (EPA/DHA) with Semax?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper